ALKS Alkermes PLC Gross Margin

This gross margin chart illustrates operating profitability dynamics, where the 79.40 metric determines this level. Alkermes plc (ALKS) generates revenue from the sale of prescription medications for CNS and addiction therapy. The company covers the global schizophrenia treatment market, leveraging its own patents and licensing royalties. High scientific authority and physician trust provide the brand with a stable reputation in psychiatry.
Financial and market metric breakdowns for Alkermes PLC (ALKS)

To distinguish a fundamentally resilient business from speculative assets, it is critical for investors to evaluate the portion of revenue remaining after covering direct production costs. By analyzing the gross profit margin, one can determine the ability of Alkermes plc (ALKS) to maintain margins amidst patent risks and raw material import disruptions, which directly confirms the operational efficiency and long-term viability of the biopharmaceutical model.